货号:A268185
同义名:
H 154/82; CGH-869
Felodipine是一种选择性的 L 型钙通道拮抗剂,具有血管选择性。其 IC50 值为 0.15 nM,能够通过作用于血管平滑肌特别是阻力血管来降低血压,具有抗高血压和诱导自噬的活性。


| 规格 | 价格 | 会员价 | 库存 | 数量 | |||
|---|---|---|---|---|---|---|---|
| {[ item.pr_size ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} | 现货 | 1周 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解

| 产品名称 | Ca2+ channel-like protein ↓ ↑ | Calcium Channel ↓ ↑ | Cav 2.2 ↓ ↑ | 其他靶点 | 纯度 | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CDC25B-IN-2 | ✔ | Akt | 99%+ | ||||||||||||||||
| Clevidipine | ✔ | 97% | |||||||||||||||||
| Verapamil HCl | ✔ | 99% | |||||||||||||||||
| Amlodipine | ✔ | 99% | |||||||||||||||||
| Amlodipine maleate | ✔ | 98% | |||||||||||||||||
| (+)-cis-Diltiazem HCl | ✔ | 99% | |||||||||||||||||
| Zegocractin |
++
Orai1/STIM1-mediated Ca2+ currents, IC50: 120 nM |
99%+ | |||||||||||||||||
| Tanshinone IIA sulfonate sodium | ✔ | 98% | |||||||||||||||||
| Ulixacaltamide |
++
hCaV3.1, IC50: 50 nM hCaV3.2, IC50: 110 nM |
99%+ | |||||||||||||||||
| Dronedarone HCl | ✔ | 95% | |||||||||||||||||
| Nitrendipine |
+
Calcium channel, IC50: 95 nM |
98% | |||||||||||||||||
| Efonidipine HCl monoethanolate | ✔ | 98% | |||||||||||||||||
| Cinnarizine | ✔ | 98% | |||||||||||||||||
| SEA0400 |
++
NCX, IC50: 33 nM |
ERK,ROS,p38 MAPK | 99%+ | ||||||||||||||||
| Fasudil HCl | ✔ | PKA,Rho | 98% | ||||||||||||||||
| ML-9 | ✔ | Akt,MLCK | 99%+ | ||||||||||||||||
| Flunarizine 2HCl |
+
Calcium channel, Ki: 68 nM |
95% | |||||||||||||||||
| Lomerizine 2HCl | ✔ | 98% | |||||||||||||||||
| Efonidipine | ✔ | 98% | |||||||||||||||||
| Levamlodipine | ✔ | 98% | |||||||||||||||||
| Nisoldipine |
++
L-type Cav1.2, IC50: 10 nM |
97% | |||||||||||||||||
| Isradipine | ✔ | 98% | |||||||||||||||||
| Lacidipine | ✔ | 98% | |||||||||||||||||
| Lercanidipine | ✔ | 99% | |||||||||||||||||
| Loureirin B | ✔ | Potassium Channel | 99%+ | ||||||||||||||||
| Tetracaine HCl | ✔ | 98% | |||||||||||||||||
| Manidipine |
+++
Calcium channel, IC50: 2.6 nM |
99% | |||||||||||||||||
| Manidipine Dihydrochlorid |
+++
Calcium channel, IC50: 2.6 nM |
98% | |||||||||||||||||
| Nicardipine | ✔ | 99% | |||||||||||||||||
| Wilforgine | ✔ | 98+% | |||||||||||||||||
| Econazole | ✔ | 99%+ | |||||||||||||||||
| Ginsenoside Rd | ✔ | NF-κB | 98% | ||||||||||||||||
| Fendiline HCl | ✔ | 98+% | |||||||||||||||||
| Mesaconitine | ✔ | 98% | |||||||||||||||||
| Tetrandrine | ✔ | 95% | |||||||||||||||||
| Nifedipine | ✔ | 98% | |||||||||||||||||
| Nilvadipine |
++++
Calcium channel, IC50: 0.03 nM |
95% | |||||||||||||||||
| Barnidipine |
++++
[3H]nitrendipine, Ki: 0.21 nM |
95+% | |||||||||||||||||
| Azelnidipine | ✔ | 97% | |||||||||||||||||
| Levetiracetam | ✔ | 98% | |||||||||||||||||
| Nimodipine | ✔ | 95% | |||||||||||||||||
| Benidipine HCl | ✔ | 98% | |||||||||||||||||
| Pinaverium bromide | ✔ | 98% | |||||||||||||||||
| Pranidipine | ✔ | 99% | |||||||||||||||||
| NP118809 |
+
L-type calcium channel, IC50: 12.2 μM N-type Ca2+ channel, IC50: 0.11 μM |
95% | |||||||||||||||||
| Amlodipine Besylate |
+++
Calcium channel, IC50: 1.9 nM |
97% | |||||||||||||||||
| Cilnidipine | ✔ | 99% | |||||||||||||||||
| Cinepazide Maleate | ✔ | 99% (HPLC) | |||||||||||||||||
| Terfenadine | ✔ | 98% | |||||||||||||||||
| YM-58483 | ✔ | 99%+ | |||||||||||||||||
| Amiloride HCl | ✔ | 98% | |||||||||||||||||
| Ranolazine | ✔ | 98% | |||||||||||||||||
| Praeruptorin A | ✔ | Akt,p38 MAPK | 98% | ||||||||||||||||
| Ranolazine 2HCl | ✔ | 98% | |||||||||||||||||
| Felodipine |
++++
L-type calcium channel, IC50: 0.15 nM |
98% | |||||||||||||||||
| PD173212 |
+++
N-type Ca2+ channel, IC50: 36 nM |
98% | |||||||||||||||||
| Levamlodipine besylate | ✔ | 97% | |||||||||||||||||
| Carboxyamidotriazole Orotate | ✔ | 98% | |||||||||||||||||
| IGS-1.76 | ✔ | 98+% | |||||||||||||||||
| WH-4-023 |
++++
Cav 2.2, IC50: 0.001 μM |
++++
Cav 2.2, IC50: 0.001 μM |
99%+ | ||||||||||||||||
| 1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。 | |||||||||||||||||||
| 靶点 |
|
| 描述 | Felodipine is a long-acting 1,4-dihydropyridine calcium channel blocker. Felodipine significantly relaxes KCl-contracted porcine coronary segments by blocking the Ca2+ channels, displaying ~50 times more potent than nifedipine (IC50 of ~8 nM) and ~430 times than verapamil (IC50 of ~65 nM) [3]. Felodipine significantly induces the transcription and secretion of IL-6 and IL-8 with ED50 values of 5.8 nM and 5.3 nM in primary human VSMC and lung fibroblasts, respectively, while propranolol or furosemide fails to affect the expression of the two IL genes[4]. Felodipine blocks the muscarinic receptor-mediated (carbachol) Ca2+-dependent contraction of guinea pig ileum longitudinal smooth muscle (GPILSM) with an IC50 of 1.45 nM[5]. In hypertensive patients, felodipine does not appear to significantly affect glomerular filtration rate, creatinine clearance, glucose tolerance, or plasma lipoprotein concentrations. In the management of hypertension, felodipine 5-40 mg/d significantly reduces systolic and diastolic BP. Adverse effects associated with felodipine are similar to those of other dihydropyridine calcium-channel antagonists and include peripheral edema, headache, dizziness, flushing, and fatigue. Felodipine appears to be safe and effective for the management of hypertension when used alone or in combination with other antihypertensive agents[6]. |
| Concentration | Treated Time | Description | References | |
| IPSC-derived human neurons | 100 nM | 5 days | Felodipine reduced levels of A53T α-synuclein. | Nat Commun. 2019 Apr 18;10(1):1817. |
| MRSE (ATCC 35984) | 8 μg/mL | 24 hours | Evaluate the antibacterial effect of felodipine on MRSE, results showed that felodipine could effectively inhibit the growth of MRSE. | Bioact Mater. 2021 Nov 24;14:272-289. |
| MRSA (ATCC 43300) | 8 μg/mL | 24 hours | Evaluate the antibacterial effect of felodipine on MRSA, results showed that felodipine could effectively inhibit the growth of MRSA. | Bioact Mater. 2021 Nov 24;14:272-289. |
| Brain tissue | 1.0 nM | 30 minutes | Measure the effect of Felodipine on [3H]-isradipine binding in brain tissue. Results showed that Felodipine significantly inhibited [3H]-isradipine binding. | Br J Pharmacol. 1994 Aug;112(4):1017-24. |
| LL29 cells | 6 µM and above | 48 hours | Inhibited TGF-β1-induced collagen production without affecting cell viability | Sci Rep. 2017 Jun 13;7(1):3439. |
| Mouse primary cortical neurons | 1 µM and 5 µM | 5 hours | Felodipine increased LC3-II levels, indicating enhanced autophagic flux. | Nat Commun. 2019 Apr 18;10(1):1817. |
| Administration | Dosage | Frequency | Description | References | ||
| Spontaneously hypertensive rats (SHR) | Spontaneously hypertensive rat model | Subcutaneous osmotic minipump | 0.4 mg/kg/day | Once daily for four weeks | Felodipine monotherapy decreased systolic blood pressure. The combination with ramipril was more effective than ramipril alone but not significantly better than felodipine monotherapy. The beneficial effect of felodipine monotherapy on left ventricular hypertrophy was less prominent than that of ramipril, but its cardioprotective effect was improved when combined with ramipril. | Br J Pharmacol. 1997 Jun;121(3):503-10 |
| Mice | Ethanol dependence model | Intraperitoneal injection | 10 mg/kg | Single dose | Evaluate the effect of Felodipine on the ethanol withdrawal syndrome. Results showed that Felodipine did not significantly alter the behavioral manifestations of ethanol withdrawal. | Br J Pharmacol. 1994 Aug;112(4):1017-24. |
| CD1 ICR mice | Skin and soft tissue infection model | Subcutaneous injection | 20 mg/kg and 40 mg/kg | Every 24 hours for 7 days | Evaluate the antibacterial effect of felodipine in a murine skin and soft tissue infection model, results showed that high-dose felodipine significantly reduced fluorescence intensity and bacterial burden at the infection site. | Bioact Mater. 2021 Nov 24;14:272-289. |
| ICR mice | Bleomycin-induced pulmonary fibrosis model | Intratracheal administration | 3.3 mg/kg | Once daily for 14 days | Prevented and treated bleomycin-induced pulmonary fibrosis, improved lung function and reduced collagen deposition | Sci Rep. 2017 Jun 13;7(1):3439. |
| Mice | B6HD (N171-82Q) mice | Intraperitoneal injections | 5 mg/kg | Three times a week for 6 weeks | Felodipine improved motor performance and reduced huntingtin aggregate numbers in B6HD mice. | Nat Commun. 2019 Apr 18;10(1):1817. |
| Mice | P301S transgenic mice (PS19) | Intraperitoneal injection | 5 mg/kg | Daily for 14 days | Felodipine significantly attenuated tau-mediated microglial activation and NLRP3 expression, and significantly reduced tau hyperphosphorylation at S202/Thr205 and Thr212/Ser214 residues by inhibiting JNK/P38 signaling. | Mol Brain. 2024 Sep 2;17(1):62 |
| Wistar-Kyoto rats | Fructose-fed rat model | Intubation | 5 mg/kg/day | Once daily for 6 weeks | Felodipine significantly attenuated the increased levels in serum IL-18 and cardiac IL-18 mRNA as well as coronary perivascular fibrosis in fructose-fed rats. | Mol Med. 2008 Jul-Aug;14(7-8):395-402 |
| 计算器 | ||||
| 存储液制备 | ![]() |
1mg | 5mg | 10mg |
|
1 mM 5 mM 10 mM |
2.60mL 0.52mL 0.26mL |
13.01mL 2.60mL 1.30mL |
26.02mL 5.20mL 2.60mL |
|
| CAS号 | 72509-76-3 |
| 分子式 | C18H19Cl2NO4 |
| 分子量 | 384.25 |
| SMILES Code | O=C(C1=C(C)NC(C)=C(C(OC)=O)C1C2=CC=CC(Cl)=C2Cl)OCC |
| MDL No. | MFCD00868316 |
| 别名 | H 154/82; CGH-869; Felodipine, Agon, Felo-Puren, Felobeta, Felocor, Felodipin, Felodur Felogamma, Fensel, Flodil, Modip, Munobal, Perfudal, Plendil, Renedil |
| 运输 | 蓝冰 |
| InChI Key | RZTAMFZIAATZDJ-UHFFFAOYSA-N |
| Pubchem ID | 3333 |
| 存储条件 |
In solvent -20°C: 3-6个月 -80°C: 12个月 Pure form Sealed in dry, 2-8°C |
| 溶解方案 |
DMSO: 105 mg/mL(273.26 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO 以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
|
沪公网安备 31011702889066号
沪ICP备2024050318号-1